dgk-in-1

DGK-IN-1, an extracted T cell activator, holds potential in leveraging tumor immunity.

DGK-IN-11 (Compound 1) is an inhibitor of diacylglycerol kinase (DGK). It exhibits inhibitory activity against DGKα and DGKγ. DGK-IN-11 regulates intracellular diacylglycerol levels and enhances T cell activation, cytokine production, and proliferation. This compound is applicable in cancer research.

DGK-IN-12 is a DGK inhibitor useful for cancer research.

DGK-IN-13 is a DGK inhibitor that can be utilized in cancer research.

R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

DGKα/ζ-IN-2 is a potent, orally active, and highly selective inhibitor of DGKα/ζ, exhibiting IC50 values of 23 nM for DGKα and 1.2 nM for DGKζ. It shows excellent selectivity over other DGK isoforms such as DGKβ and DGKγ. In the OT-1 mouse model, DGKα/ζ-IN-2 demonstrates significant and dose-dependent immune activation under antigen-presenting conditions. This compound can be utilized in research related to anti-tumor immunity.

DGKα&ζ-IN-1 (Compound II) is a DGK inhibitor that enhances T-cell function and synergistically interacts with PD-1, providing therapeutic advantages in immune and tumor contexts [1].

DGKζ-IN-4, a DGK-zeta inhibitor, is utilized as an active ingredient in pharmaceutical formulations to treat cancers associated with immune cell activation or those resistant to anti-PD-1/anti-PD-L1 antibody treatments [1].

DGKζ-IN-3 is an inhibitor of diacylglycerol kinase zeta (DGK-ζ), employed in the treatment of both liquid and solid cancers, as well as other diseases regulated by DGK-ζ [1].